Alpha 2-receptor-mediated vasoconstriction in patients with congestive heart failure.
- 1 December 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 80 (6) , 1660-1667
- https://doi.org/10.1161/01.cir.80.6.1660
Abstract
Alpha 2-Adrenoceptors exist postsynaptically to subserve vasoconstriction and presynaptically to modulate norepinephrine release into the synaptic cleft. Because adrenoceptors may down-regulate in response to chronic stimulation, we investigated the activity of alpha 2-receptor-mediated vasoconstriction in patients with congestive heart failure, who had increased levels of plasma norepinephrine. We used the isolated forearm model and intra-arterial infusions of subsystemic doses of yohimbine, a specific alpha 2-blocker, in 11 patients with heart failure and in 15 normal subjects. Yohimbine produced a dose-related increase in forearm blood flow and decrease in forearm vascular resistance. These findings were consistent with a direct vasodilator effect mediated by blockade of the postsynaptic alpha 2-vascular receptor. Furthermore, the vasodilator responses in patients with heart failure were similar to the normal subjects in terms of the percent increase in forearm blood flow, the dose-response relation, and the fractional response to hyperemia and phentolamine; thus, alpha 2-receptor-mediated vasoconstriction is neither enhanced nor down-regulated in heart failure. In addition, in patients with heart failure and in normal subjects, yohimbine produced an increase in the forearm venous norepinephrine concentration, consistent with an inhibition of the presynaptic alpha 2-receptor resulting in an augmented release of norepinephrine into the synaptic cleft. Thus, these data suggest that the postsynaptic alpha 2-receptor is an important mediator of vasoconstriction in patients with heart failure. Despite chronic elevations in plasma norepinephrine in patients with heart failure, alpha 2-receptor mechanisms subserving vasoconstriction and inhibition of norepinephrine release into the synaptic cleft are still functional in heart failure.This publication has 25 references indexed in Scilit:
- Prejunctional α-Adrenoceptor-Mediated Inhibition of Norepinephrine Release in Blood-Perfused Skeletal Muscle In SituJournal of Cardiovascular Pharmacology, 1987
- Modulation of Noradrenaline Release by Peripheral Presynaptic α2-Adrenoceptors in HumansJournal of Cardiovascular Pharmacology, 1987
- Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart FailureNew England Journal of Medicine, 1986
- Evidence for the existence of vascular alpha 2-adrenergic receptors in humans.Hypertension, 1984
- Influence of yohimbine on blood pressure, autonomic reflexes, and plasma catecholamines in humans.Hypertension, 1983
- Yohimbine induced anxiety and increased noradrenergic function in humans: Effects of diazepam and clonidineLife Sciences, 1983
- Pharmacodynamic Studies with a Specific α2-Adrenoceptor Agonist (BHT-933) in ManJournal of Cardiovascular Pharmacology, 1982
- Decreased Lymphocyte Beta-Adrenergic-Receptor Density in Patients with Heart Failure and Tolerance to the Beta-Adrenergic Agonist PirbuterolNew England Journal of Medicine, 1981
- The renin system: Variations in man measured by radioimmunoassay or bioassayKidney International, 1972
- A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failureJournal of Clinical Investigation, 1968